Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
cervical%20cancer%20-%20prevention%20-and-%20screening
CERVICAL CANCER - PREVENTION & SCREENING
Mortality due to cervical cancer can be reduced by prevention, early detection & treatment.
Vaccination may be started as early as 9 years old.
Vaccination may reduce the incidence of HPV-related disease.
Screening for cervical cancer after vaccination is still recommended because only 70% of the virus types associated w/ invasive cervical cancer consist of HPV 16 & 18 types & women may not be entirely protected if they have been infected w/ other HPV types prior to vaccination.

Cervical Cancer - Prevention & Screening References

  1. Benedet JL, Pecorelli S. Staging classification and clinical practice guidelines of gynaecological cancers by the FIGO Committee On Gynecologic Oncology. Elsevier. 2000 Sep
  2. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet. 1999 Mar;353(9156):869-873. PMID: 10093978
  3. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May;59(20):626-629. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 20508593
  4. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56:1-24. http://www.cdc.gov. PMID: 17380109
  5. Chan PK, Ho WC, Wong MC, et al. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol. 2009 Sep;81(9):1635-1644. doi: 10.1002/jmv.21575. PMID: 19623668
  6. Domingo EJ, Dy Echo AV. Epidemiology, prevention and treatment of cervical cancer in the Philippines. J Gynecol Oncol. 2009 Mar;20(1):11-16. doi: 10.3802/jgo.2009.20.1.11. PMID: 19471671
  7. Dawar M, Deeks S, Dobson S. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ. 2007 Aug;177(5):456-461. doi: 0.1503/cmaj.070771. PMID: 17724324
  8. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 Aug;24:5937-5949. PMID: 16828940
  9. Collins Y, Einstein MH, Gostout BS, et al. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol. 2006 Sep;102(3):552-562. PMID: 16979432
  10. Harper DM, Franco EL, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus type 16 and 18: follow-up from a randomised control trial. Lancet. 2006 Apr;367(9518):1274-1255. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 16631880
  11. Hymel PA. Decreasing risk: impact of HPV vaccination on outcomes. Am J Manag Care. 2006 Dec;12(17 Suppl):S473-S483. PMID: 17203991
  12. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus type 16 and 18 in young women: a randomized controlled trial. Lancet. 2004;364(9447):1757-1765. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 15541448
  13. Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jun;156(12):880-891. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 22711081
  14. Muñoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety immunogenicity and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Jun 01, 2009. Lancet. 2009 Jun;373(9679):1949-1957. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19493565
  15. Jeronimo J, Morales O, Horna J, et al. Visual inspection with acetic acid for cervical cancer screening outside of low-resource settings. Rev Panam Salud Publica. 2005 Jan;17(1):1-5. PMID: 15720875
  16. Obwegerser JH, Brack S. Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL cases. Acta Cytol. 2001;45(5):709-714. PMID: 11575648
  17. National Advisory Committee on Immunization (NACI), Public Health Agency of Canada. Update on human papillomavirus (HPV) vaccines. Canada Communicable Disease Report. 2012;38:1-62. http://www.phac-aspc.gc.ca. Accessed 31 Jan 2013
  18. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009 Oct;5(10):696-704. PMID: 19855170
  19. Ngelangel CA, Wang EH. Cancer and the Philippine Cancer Control Program. Jpn J Clin Oncol. 2002 Mar;32(Suppl 1):S52-S61. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11959878
  20. Romanowski B, de Borba PC, Naud PS, et al; GSK Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up 6.4 years [abstract]. Lancet. 2009 Dec;374(9706):1975-1985. doi: 10.1016/S0140-6736(09)61567-1. PMID: 19962185
  21. Sankaranarayanan R, Wesley R, Thara S, et al. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugols iodine (VILI) in cervical cancer sceening in Kerala, India. Int J Cancer. 2003 Sep;106(3):404-408. PMID: 12845681
  22. Paavonen J, Naud P, Salmeron J, et al; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul;374(9686):301-314. doi: 10.1016/S0140-6736(09)61248-4. PMID: 19586656
  23. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7-28. PMID: 17237032
  24. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362. PMID: 12469763
  25. Saslow D, Solomon D, Lawson HW, Castle PE, Killackey M, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172. doi: 10.3322/caac.21139. PMID: 22422631
  26. Wright TC Jr, Massad LS, Dunton CJ, for the 2006 American Society for Colposcopy and Cervical Pathology-sponsored consensus conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007 Oct;197(4):340-345. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 17904956
  27. Widdice LE, Kahn JA. Using the new HPV vaccines in clinical practice. Cleve Clin J Med. 2006 Oct;73(10):929-935. PMID: 17044318
  28. MedWormhttp://www.medworm.com/rss/index.php/OBGYN/29/http://www.medworm.com/rss/medicalfeeds/specialities/OBGYN.xml
  29. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  30. Advisory Committee on Immunization Practices. ACIP provisional recommendations for HPV vaccine. http://www.cdc.gov/vaccines. 01 Dec 2009.
  31. Centre for Health Protection, Scientific Committee on Preventable Diseases, Scientific Committee on AIDS and Sexually Transmitted Infections. Recommendation on the use of human papillomavirus (HPV) vaccine. http://www.chp.gov.hk. Feb 2008. Accessed 23 Nov 2010.
  32. Hong Kong College of Obstetricians and Gynaecologists. HKCOG guidelines: guidelines on the management of abnormal cervical cytology. Revised Nov 2008; Number 3. http://hkcog.obg.cuhk.edu.hk. Accessed 02 Mar 2010.
  33. American Cancer Society. Cervical cancer: prevention and early detection. http://www.cancer.org. 2012.
  34. Ho TH, Chew SH, Ilancheran A, et al. Cervical Screen Singapore. Management guidelines for abnormal Pap smear & preinvasive disease of the cervix. http://www.hpb.gov.sg. Accessed 02 Mar 2010.
  35. Ministry of Health Singapore. Cancer screening. MOH (Singapore). http://www.moh.gov.sg. Jan 2010. Accessed 09 Aug 2010.
  36. Ministry of Health Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines: management of cervical cancer. http://www.moh.gov.my. Apr 2003. Accessed 09 Aug 2010.
  37. Roteli-Martins C, Naud P, Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 ASO4-adjuvanted vaccine: follow-up to 8.4 years. Paper presented at 28th annual meeting of the European Society for Paediatric Infectious Diseases. 4-8 May 2010.
  38. Paavonen J, Naud P, Salmeron J, et al. P-689: End-of-study results of PATRICIA: a phase III efficacy study of HPV-16/18 ASO4-adjuvanted vaccine in young women. Paper presented at: 26th International Papillomavirus Conference & Clinical and Public Health Workshops. 2-8 Jul 2010.
  39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer screening version 2.2012. http://www.nccn.org/index.asp. Accessed 12 Sep 2012.
  40. Joseph GF. New ACOG cervical cancer screening recommendations. http://www.acog.org. Nov 2009. Accessed 02 Mar 2010.
  41. Domingo EJ, Germar MJV. Cervical cancer. In: Society of Gynecologic Oncologists of the Philippines (Foundation), Inc. Clinical Practice Guidelines. 6th ed. Makati City, Philippines: OVT-Graphic Line, Inc; 2012:1-14.
  42. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013 Apr;17(5)(Suppl 1):S1-S27. doi: 10.1097/LGT.0b013e318287d329. Accessed 18 Aug 2014. PMID: 23519301
  43. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014 Aug;63(RR-05):1-30. http://www.cdc.gov/mmwr. Accessed 16 Sep 2014. PMID: 25167164
  44. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014 Nov;13(11):1279-1290. doi: 10.1586/14760584.2014.963561. PMID: 25256262
  45. Himpunan Onkologi Ginekologi Indonesia (HOGI). Pedoman Pelayanan Medik Kanker Ginekologi. Edisi 2. Jakarta: Badan Penerbit FKUI; 2011.
  46. Markowitz L. 2-dose human papillomavirus (HPV) vaccination schedules. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/acip. 25 Jun 2014.
  47. Public Health England, Department of Health, and NHS England. HPV vaccination programme: change from 3 to 2 doses. Joint letter on HPV vaccine schedule change: 14 May 2014. GOV.UK. https://www.gov.uk. 14 May 2014.
  48. World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: WHO; 2014. http://www.ncbi.nlm.nih.gov. Accessed 04 Feb 2015:1-378.
  49. Petrosky E, Bocchini JA Jr, Hariri S, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-304. http://www.cdc.gov/mmwr. Accessed 10 Mar 2016. PMID: 25811679
  50. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov. Jul 2015. Accessed 10 Mar 2016.
  51. Denny L, Quinn M. FIGO cancer report 2015. Int J Gynaecol Obstet. 2015 Oct;131(Suppl 2):S75. doi: 10.1016/j.ijgo.2015.06.024. Accessed 08 Dec 2016. PMID: 26433677
  52. American College of Obstetricians and Gynecologists. Practice bulletin no. 157: cervical cancer screening and prevention. Obstet Gynecol. 2016 Jan;127(1):e1-e20. doi: 10.1097/AOG.0000000000001263. PMID: 26695583
  53. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Acta Cytol. 2015;59(2):121-132. doi: 10.1159/000381842. PMID: 25997404
  54. Kim DK, Riley LE, Harriman KH, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):136-138. doi: 10.15585/mmwr.mm6605e2. Accessed 17 Mar 2017. PMID: 28182599
  55. Hong Kong College of Obstetricians and Gynaecologists. HKCOG guidelines: guidelines for cervical cancer prevention and screening. Revised Nov 2016; Number 4. HKCOG website. http://www.hkcog.org.hk. Nov 2016.
  56. Philippine Cancer Society. Primary prevention of cancer. Philippine Cancer Society website. http://www.philcancer.org.ph. 2011.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
IBD: Where there’s smoke, there’s colorectal neoplasia
Jairia Dela Cruz, 6 days ago
For inflammatory bowel disease (IBD) patients, smoking cigarettes or just being exposed to secondhand smoke raises the risk of developing colorectal neoplasia, a study has found.
Standing good for heart health
Jairia Dela Cruz, 2 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.